CLOSE WINDOW
PLEASE NOTE: Interviews may take a few moments to load.
Dr. Buddy D. Ratner
Michael L. and Myrna Darland Endowed Chair in Technology Commercialization,
Professor of Bioengineering,
Professor of Chemical Engineering,
University of Washington
Listen
Recorded: 3/15/07
Dr. Buddy D. Ratner is the Michael L. and Myrna Darland Endowed Chair in Technology Commercialization, Professor of Bioengineering and Professor of Chemical Engineering at the University of Washington. He received his Ph.D. (1972) in polymer chemistry from the Polytechnic Institute of Brooklyn. Professor Ratner is a past president of the Society for Biomaterials, a fellow of the American Institute of Medical and Biological Engineering (AIMBE), a fellow of AVS The Science and Technology Society and a Fellow, Biomaterials Science and Engineering (FBSE).

Dr. Ratner served as president of AIMBE, 2002-2003. He was vice president of the Tissue Engineering Society International (TESI) 2003-2005. In 2002 he was elected a member of the National Academy of Engineering, USA.

Dr. Ratner is the author of more 400 scholarly works. His research interests include biomaterials, tissue engineering, polymers, biocompatibility, surface analysis of organic materials, self-assembly, nanobiotechnology and RF-plasma thin film deposition. He has won the Clemson Award for Contributions to the Biomaterials Literature, the C.M.A. Stine Award in Materials Science (AIChE), the Medard W. Welch Award (AVS) and the 2005-6 C. William Hall Award of the Society For Biomaterials. Dr. Ratner was most recently elected a Fellow of the American Association For the Advancement of Science (AAAS).

Ratner BioMedical Group (RBG) LLC seeks to develop and build on its portfolio of exclusively optioned and in-licensed technologies in novel biomaterials and pharmacologic agents. This will be done to advance medical care in tissue regeneration, wound healing, and unique biomaterials for enhanced drug delivery, among other applications. The Company’s broad collection of intellectual property will fuel the creation of a number of portfolio companies spanning diverse disciplines and therapies. RBG technologies stem from the intersections of materials science, engineering, modern biology and medicine, and have synergistic potential for translation to unique biomedical products and services. The company optioned exclusive license rights to 24 patents, patent applications and university technology disclosures with the intent of commercializing all these technologies.